Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Revenues | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| Operating expenses: | ||
| Research and development | 150,150 | 41,391 |
| General and administrative | 13,975 | 14,078 |
| Total operating expenses | 164,125 | 55,469 |
| Loss from operations | (164,125) | (55,469) |
| Other income (expense): | ||
| Amortization of financing costs | — | (24) |
| Interest income, net | 5,800 | 9,864 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's G&A?
- Viking Therapeutics (VKTX) reported G&A of $13.98M in Q1 2026.
- How has Viking Therapeutics's G&A changed year-over-year?
- Viking Therapeutics's G&A decreased by 0.7% year-over-year, from $14.08M to $13.98M.
- What is the long-term trend for Viking Therapeutics's G&A?
- Over 4 years (2021 to 2025), Viking Therapeutics's G&A has grown at a 45.8% compound annual growth rate (CAGR), from $10.7M to $48.39M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Viking Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude